about
Psoriasis carries an increased risk of venous thromboembolism: a Danish nationwide cohort studyNon-vitamin K antagonist oral anticoagulation agents in anticoagulant naïve atrial fibrillation patients: Danish nationwide descriptive data 2011-2013.Temporal trends in initiation of VKA, rivaroxaban, apixaban and dabigatran for the treatment of venous thromboembolism - A Danish nationwide cohort studyDuration of treatment with nonsteroidal anti-inflammatory drugs and impact on risk of death and recurrent myocardial infarction in patients with prior myocardial infarction: a nationwide cohort study.Dabigatran use in Danish atrial fibrillation patients in 2011: a nationwide studyPrognosis after percutaneous coronary intervention in patients with psoriasis: a cohort study using Danish nationwide registries.Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study.New-onset atrial fibrillation is a predictor of subsequent hyperthyroidism: a nationwide cohort study.Proton pump inhibitor use and risk of adverse cardiovascular events in aspirin treated patients with first time myocardial infarction: nationwide propensity score matched study.Benefit of clopidogrel therapy in patients with myocardial infarction and chronic kidney disease-a Danish nation-wide cohort studyTemporal trends in stroke admissions in Denmark 1997-2009.Risk of atrial fibrillation and stroke in rheumatoid arthritis: Danish nationwide cohort study.Cardioversion and Risk of Adverse Events with Dabigatran versus Warfarin-A Nationwide Cohort Study.Dialysis-Requiring Acute Kidney Injury in Denmark 2000-2012: Time Trends of Incidence and Prevalence of Risk Factors-A Nationwide StudyInitiation and persistence with warfarin therapy in atrial fibrillation according to ethnicity.Trends in One-Year Outcomes of Dialysis-Requiring Acute Kidney Injury in Denmark 2005-2012: A Population-Based Nationwide Study.Risk of Ischemic Stroke, Hemorrhagic Stroke, Bleeding, and Death in Patients Switching from Vitamin K Antagonist to Dabigatran after an Ablation.A clinical decision aid for the selection of antithrombotic therapy for the prevention of stroke due to atrial fibrillation.Familial Clustering of Venous Thromboembolism - A Danish Nationwide Cohort StudyStroke and recurrent haemorrhage associated with antithrombotic treatment after gastrointestinal bleeding in patients with atrial fibrillation: nationwide cohort study.The spectrum of thyroid disease and risk of new onset atrial fibrillation: a large population cohort study.Cardiovascular and non-cardiovascular hospital admissions associated with atrial fibrillation: a Danish nationwide, retrospective cohort study.Non-vitamin K antagonist oral anticoagulation usage according to age among patients with atrial fibrillation: Temporal trends 2011-2015 in DenmarkOutcomes Associated With Familial Versus Nonfamilial Atrial Fibrillation: A Matched Nationwide Cohort Study.Risk of bleeding related to antithrombotic treatment in cardiovascular disease.Management and prognosis of atrial fibrillation in the diabetic patient.Safety and efficacy of direct oral anticoagulants compared to warfarin for extended treatment of venous thromboembolism -a systematic review and meta-analysis.Major Bleeding Complications and Persistence With Oral Anticoagulation in Non-Valvular Atrial Fibrillation: Contemporary Findings in Real-Life Danish Patients.Thiazolidinediones are associated with a decreased risk of atrial fibrillation compared with other antidiabetic treatment: a nationwide cohort study.Ischaemic and haemorrhagic stroke associated with non-vitamin K antagonist oral anticoagulants and warfarin use in patients with atrial fibrillation: a nationwide cohort study.Risk of fracture in adults on renal replacement therapy: a Danish national cohort study.Antithrombotic Therapy and First Myocardial Infarction in Patients With Atrial Fibrillation.Familial clustering and subsequent incidence of atrial fibrillation among first-degree relatives in Denmark.Atrial fibrillation and risk of stroke: a nationwide cohort study.Renal Function and the Risk of Stroke and Bleeding in Patients With Atrial Fibrillation: An Observational Cohort Study.Metformin-associated risk of acute dialysis in patients with type 2 diabetes: A nationwide cohort study.Performance of the "CCS Algorithm" in real world patients.Substantial differences in initiation of oral anticoagulant therapy and clinical outcome among non-valvular atrial fibrillation patients treated in inpatient and outpatient settings.Net clinical benefit of antithrombotic therapy in patients with atrial fibrillation and chronic kidney disease: a nationwide observational cohort study.Risk of gastrointestinal adverse effects of dabigatran compared with warfarin among patients with atrial fibrillation: a nationwide cohort study.
P50
Q21135505-F4A616FE-EE90-4843-BD2B-9D6793E53B95Q30853679-F48DBFC8-A5C4-4DF3-A4AE-E30A3EAFD07EQ33794274-798F2BB6-FFFF-453A-A6D7-4F04F08862D1Q34183822-B13ACFB3-9637-4019-A07A-790270451C16Q34343069-9E2245B7-4216-4505-B31D-B3511202FB08Q34420240-2345F8F5-89DA-467E-851B-F2156C71CF39Q34540479-9E5312ED-FBF9-45B9-B87C-B3146E2C31BFQ34612593-1EC46DA2-0C2B-4310-8CC1-B071F6D9FE8DQ34974422-345D8329-FAED-4F63-8470-6CE1BA0A4B9CQ35026421-ACF88217-3279-49FA-823E-5745FC36ED86Q35028738-F763B5BD-54F5-4A32-A461-E993FC9F5BBCQ35815364-E09DEDAA-784B-4C90-B057-12BCA3F8ACD9Q35826224-16365AA8-FDE5-4EE1-BA78-DD531E4F7887Q35919539-9AC4287A-9483-4BEC-8239-594EE8234B6AQ36064234-88A82A05-D613-4773-B815-7EBACC7ED83EQ36085952-431D3F84-2E87-45A6-AB06-9264BF3C698FQ36113146-68E64A0B-A23E-49D4-84B4-3DFA5BDC77DCQ36203602-AD4E63FA-E647-4C83-8FF7-CF32734C0E7AQ36235766-4B55E43B-CEA6-4EC7-A2AF-808470C7F3AEQ36283049-4B1DD2DF-104F-4152-BB09-432DA9DD9ACAQ36428409-CE96E6E7-BCFB-43BF-85BC-0C18AF2AEEF3Q36584176-55BF0526-E602-48C2-B381-6BD31FDB3F19Q37166491-49A1CD00-974C-4A16-94EF-885F18F2DBA7Q37556132-039113C3-8DE6-4079-AD63-3C300DB85ED2Q38020869-CA674F50-40DB-49A2-8654-8A2D9A6BB093Q38497702-76AA2A3E-8D16-4092-9B59-B903654B70E2Q38567559-4213EE64-FA99-41AE-A3D6-C2DF424259D3Q38961671-03B8A91A-F910-439F-A196-A4AB7593E96BQ39061640-DEE5BB4C-824F-46DE-919C-A5E0E5B4323AQ39289650-0EDEC9CD-1E20-485D-96EE-89A650678F80Q39758072-B2467222-372C-4C30-99E2-04F7F54426B4Q40158295-5F7991C1-B244-48E3-A1CF-B7DAFD7921A0Q40331246-EDA1EDA4-A957-4664-B493-D5F60FD15B82Q40496126-139A6AAD-3B17-4E82-8779-C4E4F3B91E4CQ40518473-DC42B59D-AFF9-4E7D-8A46-DE34C9EFBE4DQ40618081-3632C910-E64F-44E5-B077-7ADC3BB84CBAQ40964366-CC972078-A06D-408E-9579-17E5963FD4E3Q41254704-63C54B6E-8F44-4D27-83C1-EB52799F9237Q41699006-06A33950-D43D-4126-BE55-38BA59FF19A2Q41725412-A1FA62C8-23F7-40BD-BABB-CCA6DBE9C923
P50
name
Jonas Bjerring Olesen
@en
Jonas Bjerring Olesen
@nl
type
label
Jonas Bjerring Olesen
@en
Jonas Bjerring Olesen
@nl
prefLabel
Jonas Bjerring Olesen
@en
Jonas Bjerring Olesen
@nl